Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer

Journal of Chemotherapy

Volumn 8, Issue 4, 1996, Pages 310-314

  Kiraz, S ^a   Baltali, E ^a   Guler I Barista N ^a   Benekli, M ^a,b   Icelik, ^a   Gullu I H ^a   Kars, A ^a   Tekuzman, G ^a   Firat, D ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Breast cancer; Epirubicin; Ifosfamide; Second line chemotherapy

Indexed keywords

EPIRUBICIN; IFOSFAMIDE; MESNA;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HEMATURIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NAUSEA; NEUROTOXICITY; VOMITING;

EID: 0029778135     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1996.8.4.310     Document Type: Article

References (19)

1. Harris JR, Lippman ME, Veronesi U, Millet W. Breast cancer: first of three parts. N Engl J Med 1992; 327: 319-328.
2. Pfeiffer P, Cold S, Rose C. Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use? Acta Oncol 1992; 31: 219-224.
3. Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109: 540-546.
4. Cantwell BMJ, Carmichael J, Ghani S, Harris AL. A phase II study of ifosfamide mesna with doxorubicin for adult soft tissue sarcoma. Cancer Chemother Pharmacol 198; 21: 49-52.
5. Hortobagyi GN. Activity of ifosfamidc in breast cancer: Semin Oncol 1992; 19: 36-42.
6. Sanchiz F, Milla A. High-dose ifosfamide and mesna in advanced breast cancer. Cancer Chemother Pharmacol 1990; 26 (Suppl): 91-92.
7. Hoffmann W, Weidmann B, Migeod F, Köhner J, Seeber S. Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. Cancer Chemother Pharmacol 1990; 26 (Suppl): 69-70.
8. Lange OF, Scheef W, Haase KD, et al. Palliative chemoradiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Cancer Chemother Pharmacol 1990; 26 (Suppl): 74-77.
9. Ghavamzadeh A. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil. Cancer Chemother Pharmacol 1990; 26 (Suppl): 66-68.
10. Milliward MJ, Harris AL, Cantwell BMJ. Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. Cancer 1990; 65: 2421-2425.
11. Bitran JD, Samuels BL, Marsik S, Gambino A, White L. A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. Clin Cancer Res 1995; 1: 185-188.
12. Cersosimo RJ, Hong WK. Epirubicin: A review of pharmacology, clinical activity and adverse effects of an adriamycin analogue. J Clin Oncol 1986; 4: 425-435.
13. World Health Organization. Handbook for reporting results of cancer treatment. Geneva: World Health Organization offset publication 48.
14. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958; 8: 699-712.
15. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
16. Cox DR. Regression models and life tables. J Royal Stat Soc (B) 1972; 34: 187-220.
17. Consensus Conference. Adjuvant chemotherapy for breast cancer. JAMA 1985; 254: 3461-3463.
18. Mansi JL, Coombes RC. Treatment of metastatic disease. Diagn Oncol 1991; 1: 161-167.
19. Kvinnsland S. Indication for cytostatic therapy in metastatic breast cancer. Acta Oncol 1992; 31: 215-218.